8-KLeadership Changes

JOHNSON & JOHNSON 8-K Report, Executive Changes (Dec 5, 2023)

Filed December 5, 2023For Securities:JNJ

Summary

Johnson & Johnson announced a significant addition to its Board of Directors with the election of Eugene A. Woods, MBA, MHA, effective November 30, 2023. Mr. Woods brings valuable experience as the Chief Executive Officer of Advocate Health, a major healthcare system. This appointment is noteworthy as Advocate Health is a customer of Johnson & Johnson, purchasing medical technologies and pharmaceuticals in the ordinary course of business. While this creates a related-party transaction, the company has disclosed the approximate financial scale of these dealings, with Advocate Health spending around $175 million on JNJ products in fiscal year 2022 and JNJ spending less than $1 million on clinical trials with Advocate Health. Investors should view this appointment as potentially strengthening the Board's understanding of hospital operations and customer perspectives. The disclosure of the customer relationship is standard practice and provides transparency. Mr. Woods will receive standard non-employee director compensation as outlined in the company's proxy statement. The filing also includes the press release announcing this appointment as an exhibit.

Key Highlights

  • 1Eugene A. Woods elected to Johnson & Johnson's Board of Directors, effective November 30, 2023.
  • 2Mr. Woods currently serves as the Chief Executive Officer of Advocate Health.
  • 3Advocate Health is a customer of Johnson & Johnson, with significant purchases of medical technologies and pharmaceuticals.
  • 4Disclosure of related-party transaction: Advocate Health spent approximately $175 million on JNJ products in FY2022.
  • 5Johnson & Johnson spent less than $1 million on clinical trials with Advocate Health in FY2022.
  • 6Mr. Woods will be compensated as a non-employee director according to the Company's Proxy Statement.
  • 7The press release announcing the appointment is included as an exhibit.

Frequently Asked Questions

Eugene A. Woods is the newly elected member of Johnson & Johnson's Board of Directors. His relevance stems from his role as the CEO of Advocate Health, a significant healthcare provider that purchases Johnson & Johnson's medical technologies and pharmaceuticals. This brings direct customer insight to the board.

Johnson & Johnson has disclosed that Advocate Health, where Mr. Woods is CEO, is a customer. While this represents a related-party transaction, the company has provided financial details of these dealings, indicating transparency. Mr. Woods will be compensated as a non-employee director and his duties will be subject to standard corporate governance and fiduciary responsibilities.

In fiscal year 2022, Advocate Health spent approximately $175 million on products from Johnson & Johnson. In return, Johnson & Johnson paid Advocate Health less than $1 million in connection with clinical trials. These figures are considered in the context of Johnson & Johnson's overall revenue.

As a non-employee director, Mr. Woods will receive compensation in line with the 'Director Compensation' section detailed in Johnson & Johnson's 2023 Proxy Statement. This typically involves a combination of cash retainers and stock awards.